Tigulixostat

DRUG5 trials

Sponsors

LG Chem Ltd., LG Chem, Innovent Biologics Technology Limited (Shanghai R&D Center)

Conditions

GoutGout FlareGout with hyperuricemiaHyperuricemiaTophi

Phase 1

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

CompletedNCT06189404

LG ChemGout, Hyperuricemia

Start: 2023-10-31End: 2023-11-30Updated: 2024-01-03

Phase 3

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

CompletedNCT05586958

LG ChemGout, Gout Flare, Hyperuricemia +1

Start: 2022-10-25End: 2024-12-16Updated: 2025-10-29

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

CompletedNCT05586971

LG ChemGout, Gout Flare, Hyperuricemia +1

Start: 2023-03-30End: 2025-05-06Updated: 2025-07-22

A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia

CompletedCTIS2022-501421-20-00

LG Chem Ltd.Gout with hyperuricemia

Start: 2024-04-09End: 2025-04-30Target: 690Updated: 2025-06-06

Tigulixostat (IBI128) vs Febuxostat in Gout

Active, not recruitingNCT07414394

Innovent Biologics Technology Limited (Shanghai R&D Center)Gout

Start: 2026-03-17End: 2027-10-30Updated: 2026-09-01

Related Papers

Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies.

2025-02-08